The SOLOIST-WHF trial investigated the efficacy of sotagliflozin, a dual SGLT2 and SGLT1 inhibitor, in patients with type 2 diabetes and a recent hospitalization for worsening HF. Here, SLC5A2 is linked to type 2 diabetes mellitus.